PTAB Again Rejects Kyle Bass AIA Review Bid Of Drug Patent
The Patent Trial and Appeal Board on Thursday dealt another setback to an organization with ties to hedge fund manager Kyle Bass, refusing its bid to review Jazz Pharmaceuticals Inc.'s patent...To view the full article, register now.
Already a subscriber? Click here to view full article